Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - ubiquitin
2
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
The UBE2G2 Binding Domain in the
Ubiquitin
Ligase GP78 and Methods of Use Thereof
Abstract: Cancer is the second leading cause of death worldwide. The primary cause of mortality from cancer is metastasis. While the underlying mechanisms of cancer metastasis are still being unraveled, the gp78 protein involved in ER-associated degradation (ERAD) appears to play a role in metastasis in sarcoma. Targeting gp78 may be a therapeutic option...
Published: 4/8/2024
|
Inventor(s):
Allan Weissman
,
Jennifer Mariano
,
Bo Chen
,
Yien-Che Tsai
Keywords(s):
APOPTOSIS
,
CANCER
,
Endoplasmic Reticulum
,
er
,
ERAD
,
ER-associated Degradation
,
Gp78
,
Metastasis
,
STRESS
,
Ube2G2
,
Ubiquitin
,
Weissman
Category(s):
Collaboration Sought > Licensing
,
TherapeuticArea > Oncology
,
Application > Therapeutics
,
Collaboration Sought > Collaboration
Platform Technology Using
Ubiquitin
to Improve the Delivery and Efficacy of Cytosolic Targeted Toxins
Targeted toxins (TT) are hybrid protein drugs consisting of ligands that bind to the surface of cancer cells and deliver polypeptide toxins that kill malignant cells by inactivating cytosolic protein synthesis and inducing cell death. A major challenge in the construction of targeted toxins is reducing the nonspecific binding of the toxin moiety to...
Published: 8/15/2024
|
Inventor(s):
Stephen Leppla
,
Shihui Liu
,
Thomas Morley
,
Christopher Bachran
Keywords(s):
ACTING
,
CBXXXX
,
CXXXXX
,
Cytosolic
,
EFFICACY
,
FUSIONS
,
IMPROVING
,
Targeted
,
TOXINS
,
Ubiquitin
Category(s):
Collaboration Sought > Licensing
,
Application > Therapeutics
,
TherapeuticArea > Oncology